General Information
Pfizer NAFLD C3711001
A Phase 2A, Randomized, Double Blind (Sponsor-Open), Placebo Controlled, Parallel Group Study to Assess the Pharmacodynamics, Safety and Tolerability of PF-05221304 and PF-06865571 Co-Administered for 6 weeks in Adults with Non-alcoholic Fatty Liver Disease (NAFLD)
| Protocol | C3711001 |
|---|---|
| Identifier | |
| UID | cfa57212-4910-4cc7-84f5-63d1dbc2cb6c |
| Status | Done - Archived |
| Phase | 2a |
| Category | Fatty Liver / Adult |
| Launch Year | 2018 |
| NCT Number | - |
| Created | 2018-11-12 16:36 |
| Last Updated | 2018-11-12 16:36 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-07-15 | No |
| Enrollment Open | 2019-04-22 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2019-04-09 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2019-12-03 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Pfizer |
|---|---|
| Division | Pfizer |
| Team | Pfizer |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Inventiv Health Clinical, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
